CUE
Cue Biopharma, Inc. · Healthcare · Market cap $123.8M
Insiders sold $2.4M net in the last 90 days ·3 sellers, 0 buyers· latest Form 4 filed Oct 15, 2026
Insider Buying
$100K
reported purchases (SEC code P)
Insider Selling
$2.4M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Latest filing
Oct 15, 2026
Ray Sumita
Cue Biopharma, Inc. (CUE) has 19 SEC Form 4 filings (35 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Oct 15, 2026.
Inside the rolling window, 4 insiders at Cue Biopharma, Inc. reported 1 open-market purchase totaling $100K and 7 open-market sales totaling $2.4M. The most active filer is Chief Executive Officer Lin Shao-Lee with 3 filings. Insiders have net sold $2.4M over the trailing 6 months. The most recent open-market filing is a sale of 1,844 shares by Chief Legal Compliance Officer Ray Sumita, dated Oct 12, 2026, worth $52K.
- Industry:Biotechnology
- CEO:Shao-Lee Lin
- Employees:29
- HQ:Boston, MA, US
- IPO:2018-01-02
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Legal Compliance Officer | Sale | 1,844 | $52K | Oct 15 | -8.7% | SEC ↗ | |
| VP, Prin. Accounting Officer | Sale | 1,144 | $32K | Oct 15 | -8.7% | SEC ↗ | |
| Chief Executive Officer | Sale | 11,087 | $305K | Oct 15 | -8.7% | SEC ↗ | |
Ray SumitaFirst filing | Chief Legal Compliance Officer | Sale | 8,829 | $266K | Aug 17 | -38.4% | SEC ↗ |
Meluzio Michael VincentFirst filing | VP, Prin. Accounting Officer | Sale | 5,628 | $169K | Aug 17 | -38.4% | SEC ↗ |
Lin Shao-LeeFirst filing | Chief Executive Officer | Sale | 40,000 | $1.1M | Aug 15 | — | SEC ↗ |
Lin Shao-LeeFirst filing | Chief Executive Officer | Sale | 18,258 | $523K | Aug 15 | — | SEC ↗ |
Sarraf PashaFirst filing | Director | Purchase | 10,796 | $100K | Jan 2 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does CUE have?
Cue Biopharma, Inc. (CUE) has 19 SEC Form 4 filings (35 transaction rows) in the rolling 365-day window, disclosed by 4 distinct insiders. Most recent filing: Oct 15, 2026.
When was the most recent SEC Form 4 filing for CUE?
The most recent Form 4 filing for CUE on Tracefour is dated Oct 15, 2026.
Who is the most active insider at CUE?
The most active SEC Form 4 filer at CUE in the rolling window is Chief Executive Officer Lin Shao-Lee, with 3 filings.
What is the net insider flow at CUE over the last 6 months?
Over the trailing 180 days, insiders at CUE have net sold $2.4M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at CUE in the current window?
Inside the rolling window, insiders at CUE bought $100K and sold $2.4M based on SEC Form 4 filings.
Can I get alerts for CUE insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Cue Biopharma, Inc. (CUE). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Cue Biopharma, Inc. is in the Healthcare sector.